Remove 2021 Remove Pharmacology Remove Side effects
article thumbnail

Top-10 ways for Pharma to leverage AI according to…AI

Impetus Digital

Unsurprisingly, the US FDA has reported a noticeable increase in the number of submissions that use AI/machine learning (ML) components in recent years; in 2021, they received more than 100 submissions wherein AI use was reported. In 2022, the AI-fuelled pipeline reportedly expanded at an annual rate of almost 40%.

Pharma 95
article thumbnail

Paving the way for anti-Abeta active immunotherapy

European Pharmaceutical Review

While new positive clinical data with anti-Abeta mAbs signal tremendous advancement and proof‑of-concept for the whole field, it is believed that the observed effects could still be improved and optimised in terms of greater clinical benefits, lower side effects and enhanced treatment convenience. Lowe SL, Duggan Evans C, et al.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Female sexual interest drug reaches tipping point with Phase III plans

Pharmaceutical Technology

In December 2021, Amsterdam-based Freya acquired Lybrido, a tablet consisting of testosterone and sildenafil, and Lybridos, a combination of testosterone and buspirone, from the Dutch biotech Emotional Brain. Moreover, some women may find certain side effects like sleepiness, seen with other alternatives, beneficial, adds Kingsberg and Simon.

article thumbnail

FDA drug dosage optimisation guidelines signal clinical trial reform

Pharmaceutical Technology

In 2021, the FDA granted Amgen’s (NASDAQ:AMGN) non-small cell lung cancer (NSCLC) drug Lumakras (sotorasib) an expedited approval, making it the first FDA-approved KRAS inhibitor. The demand came amid concerns that the drug causes a slew of side effects such as nausea, diarrhea, and liver issues.

FDA 115